-
May 10, 2022
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting
-
May 5, 2022
Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
-
April 21, 2022
Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations
-
March 28, 2022
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
-
March 22, 2022
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
-
January 5, 2022
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
-
January 4, 2022
Aileron Therapeutics to Present at Upcoming Investor Conferences
-
December 20, 2021
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
-
November 12, 2021
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
-
October 7, 2021
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity